bluuebunny/crossref_metadata_2025_split huggingface dataset:
Inebilizumab treatment in a patient with co-occurring AQP4-IgG positive neuromyelitis optica spectrum disorder and myasthenia gravis: a case report and literature review
Authors: Song Xiaoqian , Chen Jingjiao , Jin Chenyang , Peng Yilong , Sun Yuewen , Zheng Xueping 
Published: January 2025

ObjectiveThis study aims to delineate the clinical features underlying the concurrent disease of neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis (MG), and to identify efficacious therapeutic strategies.BackgroundNMOSD and MG are uncommon autoimmune diseases that infrequently co-exist. Despite previous reports, a consensus on treating NMOSD concurrent with MG is lacking.MethodsWe present the case of a 55-year-old female with both anti-aquaporin-4 (AQP4) antibody-positive NMOSD and anti-acetylcholine receptor (AChR) antibody-positive MG, who achieved stable disease control following treatment with inebilizumab without significant adverse effects. We also conducted a literature review to evaluate the clinical profile of this comorbidity.ResultsOur review identified 85 patients with concurrent NMOSD and MG. In 70 well-documented cases, MG predated NMOSD in 60 (85.8%) cases, with 42 (70%) patients having undergone thymectomy. Six (8.6%) patients were first diagnosed with NMOSD, and then thymectomy was performed in 2 (33.3%) MG patients. For NMOSD treatment, although most patients received steroid hormones and immunosuppressive agents, quite a few patients had persistent severe disability. Additionally, of 44 patients with clear records of disease recurrence, 31 patients(70.5%) experienced frequent relapses of optic neuritis and myelitis, ranging from 1 to 15 attacks, averaging five. The manifestations of MG are mainly included fatigability, diplopia, and blepharoptosis, with symptoms well-controlled in most patients. Our patient treated with inebilizumab for 1 year and no relapse was recorded to date.ConclusionsThough MG typically precedes NMOSD and thymectomy is frequently performed, it is not a prerequisite for NMOSD development but may represent a potential risk factor. MG generally follows a benign course, in contrast to the more aggressive nature of NMOSD. The utility of biological agents such as inebilizumab for patients with both NMOSD combined with MG warrants further attention.
Understanding trends in osteoporosis drug prescribing: implications for reducing futile biomedical research
Authors: Guillemot Jonathan R. , Abraham John W. , Tinker Anthea 
Published: January 2025

IntroductionOsteoporosis is a significant geriatric condition, considering its impact on fracture-related morbidity and mortality, particularly among older women. The interplay of clinical evidence, diagnostic tools availability, and broader societal attitudes toward aging and treatment efficacy affect medical attitude and prescribing behaviors. Using the example of osteoporosis in France and England, the study aims to unravel the intricacies of medical decision-making in geriatric care, offering insights into the evolving landscape of healthcare policy and practice, which in turn can help reduce futile biomedical research.MethodsWe employed documentary analysis and semi-structured interviews. Documentary analysis involved examining public policy documents related to osteoporosis management in England and France to identify trends in regulatory policies influencing prescribing practices. Semi-structured interviews with physicians explored prescriber decision-making processes, treatment initiation, and compliance management, providing insights into clinical practice complexities.ResultsThe policy analysis uncovered 157 documents between 2015 and 2016, updated in 2018, revealing distinct policy clusters and outliers shaping osteoporosis management in England and France. Therapeutic indications generally mirrored marketing authorizations. Reimbursable therapeutic indications in France showed fluctuating availability, reflecting changes in policy priorities and patient demographics. Clinical guidelines evolved to encompass diverse osteoporosis types and treatment options, guided by evidence-based recommendations and healthcare system considerations. Trust dynamics between physicians, pharmaceutical companies, and health authorities influenced prescribing trends, with variations in reliance on standardized protocols and collaborative decision-making observed between England and France.DiscussionUnderstanding trends in osteoporosis drug prescribing is crucial for optimizing healthcare policy and practice. Our study highlights the complex factors influencing prescribing patterns in England and France, emphasizing the role of trust in shaping physician behaviors. By addressing barriers to treatment uptake and enhancing patient outcomes, targeted interventions can be developed to reduce futile biomedical research and improve healthcare resource allocation.
[18F]FDG PET/CT versus [18F]FDG PET/MRI in staging of non-small cell lung cancer: a head-to-head comparative meta-analysis
Authors: Yu Dandan , Chen Chaolin 
Published: January 2025

PurposeThis meta-analysis aims to compare the diagnostic efficacy of [18F]FDG PET/CT and [18F]FDG PET/MRI in patients with non-small cell lung cancer (NSCLC).MethodsAn extensive literature search was conducted throughout the PubMed, Embase, and Web of Science databases for works accessible through September 2024. We included studies assessed the diagnostic efficacy of [18F]FDG PET/CT and [18F]FDG PET/MRI in NSCLC.ResultsThe meta-analysis includes six studies with a total of 437 patients. The sensitivity and specificity of [18F]FDG PET/CT and [18F]FDG PET/MRI for detecting lymph node metastasis were similar, at 0.82 (0.68–0.94) vs. 0.86 (0.70–0.97) and 0.88 (0.76–0.96) vs. 0.90 (0.85–0.94), respectively, with no significant differences (p = 0.70 for sensitivity, p = 0.75 for specificity). For distant metastasis, the sensitivity of [18F]FDG PET/CT and [18F]FDG PET/MRI was 0.86 (0.60–1.00) and 0.93 (0.63–1.00), and specificity was 0.89 (0.65–1.00) vs. 0.90 (0.64–1.00), respectively, also showing no significant differences (p = 0.66 for sensitivity, p = 0.97 for specificity).ConclusionOur meta-analysis shows that [18F]FDG PET/MRI has similar sensitivity and specificity to [18F]FDG PET/CT in identifying lymph node and distant metastases in patients with NSCLC. Additional larger sample prospective studies are needed to confirm these findings.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023479817, CRD42023479817.
Small subcortical ischemic infarction and other DWI lesions establish predictive model for MES
Authors: Zhao Liming , Xu Yicheng , Zhao Hongqin , Wang Senlin , Zhang Jiatang , Tian Chenglin , Zhang Aijuan , Zhang Zengchao , Ji Tailing , Wang Zhengang 
Published: January 2025

ObjectiveThe relationship between small subcortical ischemic infarction remains poorly characterized. Therefore, the present study aimed to investigate the association between artery-to-artery embolization and small subcortical infarctions.MethodsThis retrospective observational cross-sectional study enrolling 230 patients with acute middle cerebral artery (MCA) stroke classified into the microembolic signals-positive (MES+) and MES-negative (MES−) groups. The diffusion weighted imaging (DWI) infarction patterns in the MCA were divided into the territorial, border zone (BZ), cortical, and subcortical infarcts. We set the standard of small subcortical infarction (SCI) into two levels: &lt; 10 mm diameter and &lt;5 mm diameter. Relevant DWI parameters were used to build a nomogram for MES+, using free statistics.ResultsMES occurred in 38 of the 230 cases, yielding a positivity rate of 16.5%. BZ, SCI &lt;10 mm, cortical ischemia (CI), stenosis, white blood cell count, and gender were compared between the MES+ and MES− groups. Multivariate analysis revealed that BZ, SCI &lt; 10 mm, and CI were independently associated with MES. Based on DWI parameters, a nomogram model was built for MES+. The area under the curve of the model was 0.826 (95%CI 0.764 to 0.889). In internal cross-validation, the slope of the calibration curve was 1.000, indicating that the model accurately predicted unsuccessful treatment outcomes.ConclusionSmall subcortical infarctions are associated with MES. In the present study, we built a predictive nomogram model for MES+ based on small subcortical infarctions and other DWI parameters. This model demonstrated good performance in clinical practice.
Prognostic value of multi-PLD ASL radiomics in acute ischemic stroke
Authors: Wang Zhenyu , Shen Yuan , Zhang Xianxian , Li Qingqing , Dong Congsong , Wang Shu , Sun Haihua , Chen Mingzhu , Xu Xiaolu , Pan Pinglei , Dai Zhenyu , Chen Fei 
Published: January 2025

IntroductionEarly prognosis prediction of acute ischemic stroke (AIS) can support clinicians in choosing personalized treatment plans. The aim of this study is to develop a machine learning (ML) model that uses multiple post-labeling delay times (multi-PLD) arterial spin labeling (ASL) radiomics features to achieve early and precise prediction of AIS prognosis.MethodsThis study enrolled 102 AIS patients admitted between December 2020 and September 2024. Clinical data, such as age and baseline National Institutes of Health Stroke Scale (NIHSS) score, were collected. Radiomics features were extracted from cerebral blood flow (CBF) images acquired through multi-PLD ASL. Features were selected using least absolute shrinkage and selection operator regression, and three models were developed: a clinical model, a CBF radiomics model, and a combined model, employing eight ML algorithms. Model performance was assessed using receiver operating characteristic curves and decision curve analysis (DCA). Shapley Additive exPlanations was applied to interpret feature contributions.ResultsThe combined model of extreme gradient boosting demonstrated superior predictive performance, achieving an area under the curve (AUC) of 0.876. Statistical analysis using the DeLong test revealed its significant outperformance compared to both the clinical model (AUC = 0.658, p &lt; 0.001) and the CBF radiomics model (AUC = 0.755, p = 0.002). The robustness of all models was confirmed through permutation testing. Furthermore, DCA underscored the clinical utility of the combined model. The prognostic prediction of AIS was notably influenced by the baseline NIHSS score, age, as well as texture and shape features of CBF.ConclusionThe integration of clinical data and multi-PLD ASL radiomics features in a model offers a secure and dependable approach for predicting the prognosis of AIS, particularly beneficial for patients with contraindications to contrast agents. This model aids clinicians in devising individualized treatment plans, ultimately enhancing patient prognosis.
The effects of mirror therapy with neuromuscular electrical stimulation on motor and sensory functions in patients with common peroneal nerve injury
Authors: Chu Xiaolei , Liang Jiajia , Gao Mingwei , Zhao Xiaoxuan , Sun Jiaojiao , Liu Wenjie , Zhao Donglin , Xing Zheng , Li Qi 
Published: January 2025

BackgroundInjuries to the common peroneal nerve often result in significant sensory and motor function loss, severely affecting patients’ quality of life. Although existing treatments, including medication and surgery, provide some degree of efficacy, their effectiveness is limited by factors such as tolerance and adverse side effects.MethodsThis study aims to evaluate the effects of a 4-week regimen of mirror therapy combined with neuromuscular electrical stimulation on lower limb function, muscle strength, and sensation in patients with common peroneal nerve injuries. The objective is to identify novel therapeutic strategies for lower limb peripheral nerve injuries.30 patients with Common peroneal nerve caused by pelvic fractures were selected from the Rehabilitation Medicine Department of Tianjin Hospital between July 2023 and July 2024. They were randomly divided into two groups: the neuromuscular electrical stimulation group (n = 15) and the mirror therapy with neuromuscular electrical stimulation group (n = 15).ResultsAfter 4 weeks, it was found that mirror therapy with neuromuscular electrical stimulation has a significantly better therapeutic effect on Common peroneal nerve than simple electrical stimulation therapy, particularly in terms of superficial sensation, nerve conduction velocity and ROM.
MetaboLINK is a novel algorithm for unveiling cell-specific metabolic pathways in longitudinal datasets
Authors: Lichtarge Jared , Cappuccio Gerarda , Pati Soumya , Dei-Ampeh Alfred Kwabena , Sing Senghong , Ma LiHua , Liu Zhandong , Maletic-Savatic Mirjana 
Published: January 2025

IntroductionIn the rapidly advancing field of ‘omics research, there is an increasing demand for sophisticated bioinformatic tools to enable efficient and consistent data analysis. As biological datasets, particularly metabolomics, become larger and more complex, innovative strategies are essential for deciphering the intricate molecular and cellular networks.MethodsWe introduce a pioneering analytical approach that combines Principal Component Analysis (PCA) with Graphical Lasso (GLASSO). This method is designed to reduce the dimensionality of large datasets while preserving significant variance. For the first time, we applied the PCA-GLASSO algorithm (i.e., MetaboLINK) to metabolomics data derived from Nuclear Magnetic Resonance (NMR) spectroscopy performed on neural cells at various developmental stages, from human embryonic stem cells to neurons.ResultsThe MetaboLINK analysis of longitudinal metabolomics data has revealed distinct pathways related to amino acids, lipids, and energy metabolism, uniquely associated with specific cell progenies. These findings suggest that different metabolic pathways play a critical role at different stages of cellular development, each contributing to diverse cellular functions.DiscussionOur study demonstrates the efficacy of the MetaboLINK approach in analyzing NMR-based longitudinal metabolomic datasets, highlighting key metabolic shifts during cellular transitions. We share the methodology and the code to advance general ‘omics research, providing a powerful tool for dissecting large datasets in neurobiology and other fields.
Low-dose intranasal deferoxamine modulates memory, neuroinflammation, and the neuronal transcriptome in the streptozotocin rodent model of Alzheimer’s disease
Authors: Fine Jared M. , Kosyakovsky Jacob , Bowe Tate T. , Faltesek Katherine A. , Stroebel Benjamin M. , Abrahante Juan E. , Kelly Michael R. , Thompson Elizabeth A. , Westby Claire M. , Robertson Kiley M. , Frey William H. , Hanson Leah R. 
Published: January 2025

IntroductionIntranasal (IN) deferoxamine (DFO) has emerged over the past decade as a promising therapeutic in preclinical experiments across neurodegenerative and neurovascular diseases. As an antioxidant iron chelator, its mechanisms are multimodal, involving the binding of brain iron and the consequent engagement of several pathways to counter pathogenesis across multiple diseases. We and other research groups have shown that IN DFO rescues cognitive impairment in several rodent models of Alzheimer Disease (AD).MethodsThis study was designed to probe dosing regimens to inform future clinical trials, while exploring mechanisms within the intracerebroventricular (ICV) streptozotocin (STZ) model.ResultsFive weeks of daily IN dosing of Long Evans rats with 15 μL of a 1% (0.3 mg), but not 0.1% (0.03 mg), solution of DFO rescued cognitive impairment caused by ICV STZ administration as assessed with the Morris Water Maze (MWM) test of spatial memory and learning. Furthermore, IN DFO modulated several aspects of the neuroinflammatory milieu of the ICV STZ model, which was assessed through a novel panel of brain cytokines and immunohistochemistry. Using RNA-sequencing and pathway analysis, STZ was shown to induce several pathways of cell death and neuroinflammation, and IN DFO engaged multiple transcriptomic pathways involved in hippocampal neuronal survival.DiscussionTo our knowledge this study is the first to assess the transcriptomic pathways and mechanisms associated with either the ICV STZ model or DFO treatment, and the first to demonstrate efficacy at this low dose.
Age-dependent interaction between serum zinc and triglyceride-glucose index among American adults: National Health and Nutrition Examination Survey
Authors: Lai Jun , Li Xin-Qing , Zheng Yinglin , Liu Zongyan , Wu Qiquan , Cao Yongxiao 
Published: January 2025

IntroductionZinc plays a crucial role in glucose metabolism. The association between serum zinc and insulin resistance has recently been investigated as well, but the findings are inconsistent. The triglyceride-glucose index (TyG) is frequently utilized in epidemiological research to assess insulin resistance. The association between serum zinc levels and TyG has not yet been explored. Therefore, we designed this cross-sectional study to assess the relationship between serum zinc and TyG in adults using data from the National Health and Nutrition Examination Survey (NHANES).MethodsA cross-sectional analysis was performed on 1,610 adults aged ≥20 years who participated in the National Health and Nutrition Examination Survey (NHANES) 2011–2016. The participants were stratified by age, and the differences in log-transformed serum zinc quartiles and TyG were further evaluated in age groups &lt;60 years and ≥60 years using multivariable linear regression with an interaction test. Additionally, a restricted cubic spline (RCS) model was employed to examine the dose-response relationships between log-transformed serum zinc and TyG.ResultsIn this cross-sectional study, a significant interaction was observed between log-transformed serum zinc and TyG in individuals aged &lt;60 years and those aged ≥60 years when log-transformed serum zinc was transformed into a categorical variable (P-value for the likelihood ratio test for the interaction was P = 0.017). Additionally, in the fully adjusted analyses, the association between log-transformed serum zinc and TyG in the age &lt;60 years group demonstrated a J-shaped nonlinear pattern (P for nonlinearity = 0.014), with an inflection point at ~1.94 μg/dL. While in the age ≥60 years group, it exhibited an inverted-L shaped nonlinear pattern (P for nonlinearity &lt; 0.001***).ConclusionThere is a significant relationship between log-transformed serum zinc and TyG in adults in the United States, with age potentially influencing this association. Further prospective studies are needed to offer additional evidence and insights into these findings.
Impact of corticosteroids on the efficacy of CD19/22 CAR-T cell therapy in pediatric patients with B-ALL: a single-center study
Authors: Yang Jing , Zhang Jing , Wan Xinyu , Cai Jiaoyang , Wang Tianyi , Yang Xiaomin , Li Wenjie , Ding Lixia , Song Lili , Miao Yan , Wang Xiang , Ma Yani , Luo Chengjuan , Tang Jingyan , Gu Longjun , Chen Jing , Lu Jun , Tang Yanjing , Li Benshang 
Published: January 2025

IntroductionCorticosteroids are used for toxicity management, raising concerns about whether they may affect the anti-leukemic effects of chimeric antigen receptor (CAR)-T cells.Methods and resultsIn this study, we retrospectively analyzed patients (fined two subgroups based on disease burden. Of the 75 cases in the low disease burden (LDB) group (MRD &lt; 5%, no extramedullary disease), there was no significant difference between the use of steroids and event-free survival (EFS) (p = 0.21) and overall survival (OS) (p = 0.26), and the same was found for the 119 cases in the high disease burden (HDB) group. After eliminating the effect of consolidative transplantation on the prognosis, the EFS of the patients who did not use steroids was better (p = 0.037) in the LDB group, but the difference was not significant in the HDB group. The median cumulative dexamethasone-equivalent dose was 0.56 mg/kg, and the EFS and OS were similar in the different cumulative dose groups. Furthermore, there was no difference in the recovery of B cells and the expansion of CAR-T cell copies.Conclusion and discussionIn conclusion, under the guidance of current CRS prevention and control measures, the rational use of corticosteroids does not affect the clinical efficacy and overall survival of CAR-T cell therapy in patients with B-ALL and also does not affect the persistence of CAR-T cells in vivo, but the dosage threshold needs further clinical or experimental verification.
CD146 promotes resistance of NSCLC brain metastases to pemetrexed via the NF-κB signaling pathway
Authors: Qu Hao , Fang Yan , Zhang Feng , Liu Wenwen , Xia Shengkai , Duan Wenzhe , Zou Kun 
Published: January 2025

IntroductionPemetrexed is a first line drug for brain metastases from lung cancer, either as monotherapy or combined with other drugs. The frequent occurrence of initial and acquired resistance to pemetrexed results in limited treatment effectiveness in brain metastases. CD146 was recently found to play important roles in chemoresistance and tumor progression. However, the underlying mechanisms of CD146’s effects in pemetrexed resistance remain undefined.Method and resultsSensitivity to pemetrexed was assessed with a preclinical brain metastasis (BM) model based on lung adenocarcinoma PC9 cells. The role and mechanism of CD146 in pemetrexed resistance in non-small cell lung cancer (NSCLC) brain metastasis were explored in vitro and in vivo. A subpopulation of brain metastatic cells derived from progenitor PC9 cells (PC9-BrMS) was significantly resistant to pemetrexed. CD146 levels were significantly increased in pemetrexed resistant brain metastases, while CD146 inhibition suppressed pemetrexed resistance in BM cells. Mechanistically, CD146 mediated pemetrexed resistance in brain metastatic cells by promoting DNA damage repair, maintaining normal cell cycle progression, and regulating the NF-KB pathway to counter apoptosis, and these effects was based on increased DNA damage, cell cycle arrest, and occurrence of apoptosis after CD146 inhibition as well as the reemergence of pemetrexed resistance after CD146 restoration.DiscussionIn summary, this study revealed that the resistance of NSCLC brain metastatic cells to PEM was dependent on CD146.Thus CD146 might be targeted in clinic to overcome pemetrexed resistance in brain metastases from NSCLC.